Abivax (ABVX) Change in Account Payables (2024 - 2026)

Abivax's Change in Account Payables history runs 3 years deep, the most recent figure standing at -$9.4 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 170.23% year-over-year to -$9.4 million in Q1 2026; TTM through Mar 2026 was -$31.7 million, a 820.02% decrease from a year earlier, with the FY2025 full-year figure at -$7.2 million, down 93.93% from the prior year.
• Change in Account Payables retreated to -$9.4 million in Q1 2026 per ABVX's latest filing, from $9.4 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $15.0 million in Q3 2024 and bottomed at -$32.7 million in Q3 2025.
• The 3-year median for Change in Account Payables is $1.1 million (2025), against an average of -$2.4 million.
• Biggest YoY gain for Change in Account Payables was 5088.78% in 2025; the steepest drop was 318.09% in 2025.
• Year by year, Change in Account Payables stood at $180592.6 in 2024, then surged by 5088.78% to $9.4 million in 2025, then plunged by 200.55% to -$9.4 million in 2026.
• Per Business Quant, the three latest ABVX Change in Account Payables figures stand at -$9.4 million (Q1 2026), $9.4 million (Q4 2025), and -$32.7 million (Q3 2025).